Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evolocumab plus intensive statin for symptomatic intracranial atherosclerotic stenosis in acute ischemic stroke
ChiCTR2200058029Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Jinan University
- Start
- Mar 2022
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of evolocumab and ulinastatin in Cerebral atherosclerotic stenosis (ICAD) and ischemic stroke, sponsored by First Affiliated Hospital of Jinan University. Primary endpoint: Proportion of plaque volume change in stenotic vessels at 90 days. Planned start Mar 2022; status: not yet recruiting.
02
Drugs
evolocumabulinastatin
03
Conditions
Cerebral atherosclerotic stenosis (ICAD)ischemic stroke
Beyond the preview
Go deeper on ChiCTR2200058029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058029.